Indefinite Delivery Contract SPE2DX16D9418

The Defense Logistics Agency (DLA) awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the recurring medical supply needs of military healthcare facilities and veterans' medical centers nationwide.

Under this IDC, the DLA has awarded multiple delivery order contracts to DMS Pharmaceutical Group, with a combined ceiling value exceeding $450,000, for the delivery of specialized pharmaceutical items such as Xolair, Trikafta, Keytruda, Botox, and Nucala, as well as a diverse array of other prescription drugs and medical supplies. These delivery orders are firm fixed-price contracts that do not utilize any set-aside designations, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains to support the Department of Defense's medical operations.